Author + information
- Anselm K. Gitta,b,
- Dominik Lautscha,b,
- Martin Horacka,b,
- Philippe Brudia,b,
- Larry Liua,b,
- Gaetano De Ferraria,b,
- Kian Keong Poha,b and
- Jean Ferrièresa,b
Background: The objective of the second Dyslipidemia International Study (DYSIS II) was to document use of lipid-lowering therapies (LLTs), LDL-C target value attainment (LDL-C <70 mg/dL) at the time of the acute event and at 4-months follow-up in patients with acute coronary syndrome (ACS).
Methods: The ACS cohort of DYSIS II included patients from 18 countries (8 Asian, 5 European, and 5 Middle East). Evaluations were performed at the time of admission, at discharge, and 120 ± 15 days following the date of admission (the follow-up time point).
Results: Of the 3,867 patients enrolled, 2,521 were on LLT at admission. Most treated patients received statin monotherapy (89.8% at admission and 86.7% at follow-up). Few patients received combinations of statins with ezetimibe (4.1% at admission, 6.3% at follow-up) or other therapies (3.2% at admission, 3.6% at follow-up). Statin dose was increased during hospitalization for ACS but no further LLT-adjustment did take place afterwards. LDL-C <70mg/dl was achieved in 24.8% at admission and in 34.4% at follow-up. Chronic kidney disease (OR 1.52, 95% CI 1.09-2.13), diabetes (OR 1.33, 95% CI 1.08-1.64), and higher atorvastatin doses (OR 1.01, 95% CI 1.004-1.016) were predictors of LDL-C target attainment.
Conclusions: DYSIS II ACS showed that in patients with ACS statin dose was increased during hospital stay but no further adaptation of LLT did take place during FU. Only 34.4% of patients achieve the recommended LDL-C target <70mg/dl even 4 months after the ACS event.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Advances in Cholesterol Measurement and Management
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1106-047
- 2017 American College of Cardiology Foundation